New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
17:37 EDTICPTIntercept Pharmaceuticals initiates Phase 2 NASH tiral of OCA in Japan
Intercept Pharmaceuticals announced that its partner Dainippon Sumitomo Pharma, or DSP, has initiated a phase 2 clinical trial of obeticholic acid, or OCA, in adult nonalcoholic steatohepatitis, or NASH, patients in Japan. The trial is studying the efficacy and safety of a once daily dose of OCA, with the goal of randomizing 200 NASH patients to receiving OCA or placebo. The primary endpoint will be evaluated by histological improvement. DSP expects to complete the trial in the first half of 2016.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
April 13, 2015
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information
April 9, 2015
08:20 EDTICPTWedbush reiterates $493/share acquisition value for Intercept
Subscribe for More Information
April 8, 2015
06:57 EDTICPTIntercept added to short-term buy list at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use